Boston Scientific Announces Launch of Kinetix(TM) Guidewire
NATICK, Mass., April 22 /PRNewswire-FirstCall/ — Boston Scientific Corporation (NYSE: BSX) today announced the launch of its new Kinetix(TM) Guidewire for use in percutaneous coronary intervention (PCI) procedures. Guidewires are small flexible wires physicians use to deliver interventional devices such as drug-eluting stents. The Kinetix Guidewire features a unique micro-cut nitinol sleeve designed for significantly improved torque control compared to conventional spring coil guidewires. The Kinetix Guidewire represents the first major advance in coronary guidewire technology in nearly a decade. The Company will begin a phased launch of the Kinetix Guidewire immediately and expand to full product availability by next quarter.
Joseph DeGregorio, M.D., treated the first patient with the Kinetix Guidewire at Hackensack University Medical Center in Hackensack, New Jersey, marking the first procedure worldwide to employ this advanced coronary guidewire.
“The Kinetix Guidewire provided exceptional torque and flexibility,” said Dr. DeGregorio. “It’s rare to find a workhorse guidewire that combines outstanding deliverability of the wire, support for device deliverability and an excellent safety profile. The availability of Kinetix is welcome news for interventional cardiologists and their patients.”
The Kinetix Guidewire builds on Boston Scientific’s SynchroÃ‚® Guidewires used in neurovascular interventions. The micro-cut nitinol sleeve and a nitinol distal core are designed to provide increased torque transmission and flexibility while providing a soft distal tip that physicians often demand in a workhorse guidewire. The responsiveness and maneuverability of the Kinetix Guidewire is designed to deliver excellent performance, safety and ease of use, benefiting both patient and physician.
“We’re pleased to begin offering this innovative technology that should help physicians simplify coronary angioplasty procedures,” said Hank Kucheman, Executive Vice President and President of Boston Scientific’s Cardiology, Rhythm and Vascular Group. “Kinetix reinforces our commitment to providing improved treatment options that promote better patient outcomes.”
Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: www.bostonscientific.com.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like “anticipate,” “expect,” “project,” “believe,” “plan,” “estimate,” “intend” and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding product performance, competitive offerings, procedural volume, overall market size and our market position. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.
Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and, future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A – Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A – Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.
CONTACT: Paul Donovan 508-650-8541 (office) 508-667-5165 (mobile) Media Relations Boston Scientific Corporation Larry Neumann 508-650-8696 (office) Investor Relations Boston Scientific Corporation
SOURCE Boston Scientific Corporation